Molecular Characterization of Glioblastoma and Tumor Microenvironment

Glioblastoma is an aggressive primary brain tumour characterised by profound molecular heterogeneity and a complex microenvironment that underlies its therapeutic resistance and dismal prognosis. High-throughput genomic, epigenomic and transcriptomic profiling has defined distinct molecular subtypes driven by alterations in EGFR, IDH1, PDGFRA and NF1, as well as DNA methylation patterns that further stratify patient outcomes. Single-cell and spatial-omics approaches have illuminated intratumoural diversity, mapping cancer cells along a developmental hierarchy and revealing glial progenitor-like stem cells that sustain growth. Concurrently, the surrounding milieu—comprising tumour-associated macrophages and microglia, vascular cells, pericytes and extracellular matrix components—regulates invasion, immune evasion and therapy response. Hypoxia acts as a global organiser of tumour architecture, shaping cellular niches and driving adaptive transcriptional programmes. Together, these insights provide a comprehensive framework for precision medicine, pinpointing novel targets such as splicing-derived neoantigens, lineage-specific vulnerabilities and microenvironmental dependencies to inform improved treatment strategies.

Research from Nature Portfolio

Recent studies have leveraged single-cell transcriptomics to map glioblastoma cellular heterogeneity onto developmental lineages, revealing a conserved tri-lineage hierarchy centred on glial progenitor-like stem cells that drive proliferation and represent potential therapeutic targets. In parallel, analyses of tumour-wide RNA splicing aberrations have uncovered a novel class of shared neoantigens resulting from recurrent neojunctions; these epitopes are presented across diverse tumour regions and can be recognised by CD8+ T cells, offering a promising avenue for immunotherapies that overcome intratumoural heterogeneity.

Molecular Characterization of Glioblastoma and Tumor Microenvironment publication trend

The graph below shows the total number of articles in molecular characterization of glioblastoma and tumor microenvironment across all publications each year (not limited to Nature Index journals).

Technical terms

Single-cell RNA sequencing (scRNA-seq): A high-resolution technique for profiling gene expression in individual cells.

Spatial transcriptomics: A method that maps gene expression to precise locations within tissue sections.

Glioblastoma stem cells: Rare tumour cells with self-renewal capacity that drive tumour growth and heterogeneity.

Neoantigens: Novel peptide sequences arising from tumour-specific genetic or splicing alterations that can be recognised by the immune system.

Hypoxia: A microenvironmental state of reduced oxygen tension that influences cellular metabolism, gene expression and tissue organisation.

References

1. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature (2025).
2. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell (2024).
3. Transcriptome analysis reveals tumor microenvironment changes in glioblastoma. Cancer Cell (2023).
4. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010).
5. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nature Communications (2020).
6. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell (2022).